FDA clears Heart Force's ballistocardiograph
This article was originally published in Clinica
A digital ballistocardiograph (dBG) developed by Heart Force Medical has received 510(k) clearance from the US FDA. The dBG 300 device is a standalone, portable noninvasive cardiac performance monitor; it employs digital sensors to measure the recoil of the human body due to the momentum of the blood pumped by the heart. Vancouver, Canada-based Heart Force Medical intends the device to be used to monitor patients in critical care, as well as assessing cardiac performance other patients.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.